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Background: Understanding the function of FFA2 has been slowed by a lack of selective orthosteric ligands.
Results: Residues within FFA2 that dictate the recognition and function of potent and selective orthosteric agonists are
described.
Conclusion: Key aspects of ligand interaction with the orthosteric binding pocket of FFA2 are defined.
Significance: This work will be invaluable in future drug development at the FFA2 receptor.
FFA2 is a G protein-coupled receptor that responds to short
chain fatty acids and has generated interest as a therapeutic tar-
get for metabolic and inflammatory conditions. However, defi-
nition of its functions has been slowed by a dearth of selective
ligands that can distinguish it from the closely related FFA3. At
present, the only selective ligands described for FFA2 suffer
from poor potency, altered signaling due to allosteric modes of
action, or a lack of function at non-human orthologs of the
receptor. To address the need for novel selective ligands, we
synthesized two compounds potentially having FFA2 activity
and examined themolecular basis of their function. These com-
pounds were confirmed to be potent and selective orthosteric
FFA2 agonists. A combination of ligand structure-activity rela-
tionship, pharmacological analysis, homologymodeling, species
ortholog comparisons, and mutagenesis studies were then
employed to define the molecular basis of selectivity and func-
tion of these ligands. From this, we identified key residues
withinboth extracellular loop2 and the transmembranedomain
regions of FFA2 critical for ligand function.One of these ligands
was active with reasonable potency at rodent orthologs of FFA2
and demonstrated the role of FFA2 in inhibition of lipolysis and
glucagon-like peptide-1 secretion in murine-derived 3T3-L1
and STC-1 cell lines, respectively. Together, these findings
describe the first potent and selective FFA2 orthosteric agonists
and demonstrate key aspects of ligand interaction within the
binding site of FFA2 that will be invaluable in future ligand
development at this receptor.
Gprotein-coupled receptors (GPCRs)2 activated by free fatty
acids have generated significant interest in recent years for their
potential use as therapeutic targets in the treatment of various
metabolic and inflammatory conditions. These GPCRs include
a family of four receptors: two that respond to long chain fatty
acids (FFA1 (previously GPR40) and FFA4 (previously
GPR120)) and two that respond to short chain fatty acids
(SCFAs) (FFA2 (previously GPR43) and FFA3 (previously
GPR41)). Although the long chain fatty acid receptors have
received the most interest, FFA1 due to its ability to potentiate
glucose-stimulated insulin release (1) and FFA4 for its ability to
stimulate glucagon-like peptide-1 secretion (2) and to mediate
the insulin-sensitizing and anti-inflammatory properties of n-3
fatty acids (3), the SCFA receptors, and particularly FFA2, have
also generated significant interest. However, the development
and validation of FFA2 as a therapeutic target has been hin-
dered greatly by a lack of suitably selective ligands for this
receptor over the closely related FFA3 (4).
Although both FFA2 and FFA3 respond to the same group of
SCFA ligands, they display clear differences in the rank order of
potency for these ligands. Of particular interest, human FFA2
(hFFA2) responds with equal potency to acetate (C2) and pro-
pionate (C3), whereas hFFA3 displays greater potency for C3
than for C2 (5–7). Although this observation has led to some
use of C2 as a selective agonist for FFA2 (8, 9), both the potency
and selectivity for C2 at hFFA2 remain low (10), making it
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impractical to use this ligand effectively to differentiate clearly
between FFA2 and FFA3 function. More importantly, we have
recently demonstrated that although the rank order difference
is maintained, the selectivity for C2 is not preserved in
the rodent orthologs of FFA2 and FFA3, where C2was found to
be equipotent at mouse FFA2 (mFFA2) and mFFA3 (11).
Clearly, this demonstrates a need for synthetic ligands that can
differentiate between the function of these receptors in both
human and rodent systems.
Early attempts to identify synthetic ligands for FFA2 revealed
a series of phenylacetamides, exemplified by 4-chloro--(1-
methylethyl)-N-2-thiazolylbenzeneacetamide (4-CMTB), as
the first reasonably potent and selective agonists of this recep-
tor (12). However, detailed examination of the pharmacology of
these compounds has demonstrated that they are in fact ago-
allosteric modulators of FFA2, binding to a site distinct from
the endogenous SCFAs (12, 13). Although 4-CMTB is active at
rodent orthologs of FFA2 (11) and has been used to define some
aspects of FFA2 function (12, 14), it is also apparent that as an
allosteric modulator, signaling responses to 4-CMTB at FFA2
are not identical to those of the endogenous SCFAs (13). Con-
sidering this, there is clearly a need to developnovel FFA2 selec-
tive ligands with properties more similar to, and which ideally
bind to the same site as, the endogenous SCFAs. To date, the
only study describing selective orthosteric agonists for FFA2
examined the structure-activity relationship of small carboxylic
acids to identify a number of compounds with modest selectiv-
ity for both FFA2 and FFA3 (10). However, due to their rela-
tively small size and resulting low binding energy, the potency
of these small carboxylic acid agonists remains low.
Selective antagonists for the SCFA receptors would be
equally useful in helping to define the specific functions of FFA2
compared with FFA3, and, indeed, at least one FFA2 antago-
nist/inverse agonist, (S)-3-(2-(3-chlorophenyl)acetamido)-4-
(4-(trifluoromethyl)phenyl) butanoic acid (CATPB), has been
described (15). However, the practical utility of this compound
is reduced substantially by the fact that it appears to be highly
selective for the human ortholog, with no significant affinity at
mFFA2 (11). Given the lack of potent and selective orthosteric
agonists or antagonists with activity in non-human systems,
there is clearly a substantial need for novel FFA2 ligands if the
function of this receptor is to be fully explored and understood.
To address this need, we identified compounds from the pat-
ent literature with reported activity at FFA2 that we hypothe-
sized were likely to be orthosteric agonists, based primarily on
the presence, as in the SCFAs, of a carboxylate moiety (16). We
synthesized two compounds based on the structures described
and examined their function at human and rodent orthologs of
the FFA receptors. This confirmed these compounds to be
potent and selective orthosteric FFA2 agonists. We then used a
combination of ligand-based structure activity, detailed phar-
macological and functional analysis, homology modeling, spe-
cies ortholog comparisons, and mutational analysis to define
key molecular determinants of how these ligands interact with
FFA2 and then used the ligand with similar potency at human
and mouse FFA2 to define the role of this receptor in both the
regulation of lipolysis in model adipocytes and in the release of
the incretin glucagon-like peptide-1 (GLP-1) from enteroendo-
crine cells.
EXPERIMENTAL PROCEDURES
Materials—FFA2 ligands were synthesized based on the
methods described previously (16). The identity of each com-
poundwas confirmed byNMR spectroscopy. Synthesized com-
pound, compound 1 (see Fig. 1), was 3-benzyl-4-(cyclopropyl-
(4-(2,5-dichlorophenyl)thiazol-2-yl)amino)-4-oxobutanoic acid.
The purity of this compoundwas determined byHPLC analysis
performed using a Dionex 120 C18 column (5 m, 4.6  150
mm) with 10% acetonitrile in water (0–1 min), 10–100% ace-
tonitrile in water (1–10 min), 100% acetonitrile (11–15 min),
both solvents containing 0.05% TFA as modifier, a flow of 1
ml/min, and UV detection at 230 and 254 nm. Rt  15.9 min,
99% pure. 1HNMR (400MHz, CDCl3)  11.64 (br s, 1H), 7.96
(d, J 2.6 Hz, 1H), 7.62 (s, 1H), 7.41–7.10 (m, 7H), 4.18 (s, 1H),
3.14–2.85 (m, 4H), 2.56–2.48 (m, 1H), 1.26–1.22 (m, 4H); 13C
NMR (101 MHz, CDCl3)  177.2, 176.7, 137.7, 134.7, 132.8,
131.6, 131.1, 130.2, 129.2, 128.98, 128.95, 128.8, 128.5, 127.7,
127.1, 41.4, 38.7, 35.6, 33.0, 11.4; ESI-HRMS calculated for
C23H20Cl2N2O3S (M  H) 475.0641, found 475.0644). The
ClogP of this compoundwas calculated to be 5.2 using the Chem-
BioDraw software package. Compound 2 is (R)-3-(cyclopentyl-
methyl)-4-(cyclopropyl-(4-(2,6-dichlorophenyl)thiazol-2-yl)amino)-
4-oxobutanoic acid. 1H NMR (400 MHz, CDCl3)  (ppm): 7.38
(1H, d, J 8.1 Hz), 7.24–7.22 (2H, m), 7.05 (1H, br s), 3.23–3.17
(1H,m), 2.95 (1H, dd, J 16.6, 10.5Hz), 2.65 (1H, dd, J 16.6, 4.3
Hz), 1.92–1.74 (3H, m), 1.71–1.49 (5H, m), 1.34–1.19 (4H, m),
1.18–1.05 (2H, m), 1.00–0.90 (2H, m). A ClogP of 5.4 was calcu-
lated for compound 2. The methyl ester of compound 2 was
(R)-3(cyclopentylmethyl)-4-(cyclopropyl(4-(2,6-dichlorophenyl)-
thiazol-2-yl)amino)-4-oxobutanoic acid methyl ester; 1H NMR
(400MHz,CDCl3) (ppm):7.40–7.39 (1H,m),7.38–7.37 (1H,m),
7.24–7.21 (1H,m), 7.03 (1H, br s), 4.02–3.94 (1H,m), 3.68 (3H, s),
3.23–3.18 (1H,m),2.93 (1H,dd, J17.1,10.0Hz),2.61 (1H,dd, J
17.1, 5.2 Hz), 1.90–1.73 (4H, m), 1.67–1.47 (5H, m), 1.34–1.18
(3H, m), 1.17–1.06 (2H, m), 1.02–0.95 (1H, m). The tert-butyl
ester ester of compound2was (R)-3(cyclopentylmethyl)-4-(cyclo-
propyl(4-(2,6-dichlorophenyl)thiazol-2-yl)amino)-4-oxobutanoic
acid tert-butyl ester; 1H NMR (400 MHz, CDCl3)  (ppm): 7.42
(1H, d, J 8.1 Hz), 7.26–7.24 (2H, m), 7.06 (1H, br s), 3.27–3.21
(1H,m), 2.97 (1H, dd, J 17.0, 10.0Hz), 2.65 (1H, dd, J 17.0, 4.3
Hz), 1.95–1.76 (3H,m), 1.74–1.54 (3H,m), 1.62 (9H, s), 1.44–1.21
(5H, m), 1.20–1.10 (3H, m), 1.06–0.90 (2H, m).
4-CMTB was synthesized as described previously (13). The
hFFA2 antagonist/inverse agonist CATPB was synthesized as
described previously (11). The FFA4 agonist, 3-(4-((4-fluoro-
4-methyl-[1,1-biphenyl]-2-yl)methoxy)phenyl)propanoic acid
(TUG-891), was synthesized as described by Shimpukade et al.
(17). Tissue culture reagents were from Invitrogen. Molecular
biology enzymes and reagents were from Promega (Southamp-
ton, UK). The radiochemical [35S]GTPS was from Perkin-
Elmer Life Sciences. All other experimental reagents were from
Sigma.
Plasmids and Mutagenesis—All plasmids used encoded
either human, mouse, or rat FFA1–4 receptors with enhanced
yellow fluorescent protein (eYFP) fused to their C termini in the
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pcDNA5 FRT/TO expression vector as described previously
(11, 13, 17, 18). A chimeric form of hFFA2, in which extracel-
lular loop 2 (ECL2) was replaced with ECL2 from hFFA3 was
also as reported previously (13). All individual point mutations
described were introduced using the QuikChange method
(Stratagene).
Cell Culture, Transfection, and Stable Cell Lines—For exper-
iments utilizing transient heterologous expression, HEK293T
cells were used. Cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS at 37 °C
and 5% CO2. Transfections were carried out using polyethyl-
eneimine, and experiments were conducted 48 h post-transfec-
tion. In experiments where stable cell lines were employed, the
Flp-InTM T-RExTM system (Invitrogen) was used to generate
293 cellswith tetracycline- or doxycycline-inducible expression
of the receptor of interest. To generate these cell lines, Flp-InTM
T-RExTM 293 cells were co-transfected with the pOG44 vector
and the receptor of interest in pcDNA5/FRT/TO. Transfection
with pOG44 drives expression of Flp recombinase, which,
in turn, allows for recombination between FRT sites in
pcDNA5/FRT/TO and in the genome of the Flp-InTM
T-RExTM 293 cells, thus allowing identification of stable induc-
ible cells for the receptor of interest to be generated by appro-
priate antibiotic selection. All experiments carried out using
these cells were conducted after a 24-h treatment with 100
ng/ml doxycycline to induce expression of the receptor of
interest.
For experiments using differentiatedmouse adipocytes, sub-
confluent 3T3-L1 fibroblasts were maintained in DMEM sup-
plementedwith 10%newborn calf serumand incubated at 37 °C
and 10% CO2. At 2 days postconfluence, growth-arrested cells
were differentiated to 3T3-L1 adipocytes by the addition of
DMEM containing 10% FBS, 0.5 mM methyl isobutylxanthine,
0.25 M dexamethasone, 1 g/ml bovine insulin, and 5 M tro-
glitazone. After a 72-h incubation (day 3), cells were supple-
mentedwithDMEMcontaining 10% FBS, 1g/ml bovine insu-
lin, and 5M troglitazone. At day 6, the cells were changed into
DMEM containing 10% FBS for 2 days, prior to use 9–14 days
postdifferentiation.
The human-derived liposarcoma cell line SW872 was main-
tained in DMEM supplemented with 10% FBS and maintained
at 37 °C and 10% CO2. To differentiate these cells into adi-
pocytes, cells were plated in 12-well plates and cultured until
confluent. Culture medium was then replaced with medium
supplemented with 0.5 mM methyl isobutylxanthine, 1 M
dexamethasone, 10 g/ml bovine insulin, and 500 M oleic
acid. After a 72-h incubation, culture medium was replaced
with medium containing 10 g/ml bovine insulin and 500 M
oleic acid. Culture medium was then replaced every 48 h with
fresh medium supplemented only with 500 M oleic acid until
cells were used for experiments between days 10 and 14. To
confirm differentiation, cells were fixed with 4% paraformalde-
hyde and stained with oil red O to demonstrate lipid
accumulation.
STC-1 enteroendocrine cells were maintained in DMEM
supplemented with 10% FBS and maintained at 37 °C and 10%
CO2. For experiments, cells were plated in 24-well plates and
cultured for at least 24 h before initiating GLP-1 secretion
experiments.
[35S]GTPS Incorporation Assay—Cell membrane prepara-
tions were generated from Flp-InTM T-RExTM 293 cells
induced to express the receptor of interest, as described previ-
ously (18). [35S]GTPS binding experiments were performed
according to a method described previously (10). Briefly, cell
membrane preparations containing 5 or 10 g of protein were
added to assay buffer (50 mM Tris-HCl, pH 7.4, 10 mM MgCl2,
100mMNaCl, 1 mM EDTA, 1MGDP, and 0.1% fatty acid-free
bovine serum albumin) containing the appropriate concentra-
tions of ligand and allowed to reach equilibrium by preincubat-
ing for 15 min at 25 °C. To initiate the assay, 50 nCi of
[35S]GTPS was added to each tube, and the reaction was ter-
minated by rapid filtration through GF/C glass filters using a
24-well Brandel cell harvester (Alpha Biotech, Glasgow, UK)
after a 1-h incubation at 25 °C. Unbound [35S]GTPS was
washed from filters by three washes with ice-cold wash buffer
(50mMTris-HCl, pH7.4, and 10mMMgCl2) before the remain-
ing bound [35S]GTPS was measured by liquid scintillation
spectrometry.
Bioluminescence Resonance Energy Transfer (BRET)-Arres-
tin-2 Recruitment Assay—A plasmid encoding an eYFP-tagged
form of the receptor to be assayed was co-transfected in a 4:1
ratio with a -arrestin-2 Renilla luciferase (Rluc) plasmid. Cells
were then transferred into white 96-well plates 24 h post-trans-
fection. Then 48 h post-transfection, cells werewashed, and the
culture medium was replaced with Hanks’ balanced salt solu-
tion (HBSS) immediately prior to conducting the assay. To
measure -arrestin-2 recruitment, the Rluc substrate coelen-
terazine h was added to a final concentration of 2.5 M, and
then cells were incubated for 10 min at 37 °C, test compounds
were added, and cells were incubated for a further 5 min at
37 °C. BRET resulting from receptor--arrestin-2 interaction
was then assessed by measuring the ratio of luminescence at
535 and 475 nm using a Pherastar FS fitted with the BRET1
optic module (BMG Labtech, Aylesbury, UK).
Intracellular Ca2 Mobilization Assay—All Ca2 experi-
ments were carried out using Flp-InTM T-RExTM stable induc-
ible cell lines treated with doxycycline (100 ng/ml) to induce
expression of the receptor of interest. Cells were plated 50,000/
well in black 96-well plates with clear bottoms and then allowed
to adhere for 3–6 h. Doxycycline was then added to induce
receptor expression, and cells were maintained in culture over-
night. Prior to the assay, cells were labeled for 45 min with the
calcium-sensitive dye Fura-2 AM and then washed and incu-
bated for 15minwithHBSS. Fura-2 fluorescent emission at 510
nm resulting from 340- or 380-nm excitation was then moni-
tored using a Flexstation (Molecular Devices, Sunnyvale, CA)
plate reader. Base-line fluorescence was measured for 16 s, test
compounds were then added, and fluorescence was measured
for an additional 74 s. The base line-subtracted maximum 340/
380-nm ratio obtained after the compound addition was then
used to plot concentration-response data.
Extracellular Signal-regulated Kinase 1/2 (ERK) Assay—All
ERK phosphorylation experiments were carried out using
Flp-InTMT-RExTM stable inducible cell lines treatedwith doxy-
cycline (100 ng/ml) to induce expression of the receptor of
Selective FFA2Orthosteric Agonists
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interest. Briefly, 75,000 cells were seeded per well in a 96-well
plate and then allowed to attach for 3–6 h before the addition of
doxycycline to induce receptor expression. After incubating
overnight, the culture medium was replaced with serum-free
DMEM containing doxycycline (100 ng/ml), and cells were
then incubated for a further 5–6 h prior to the assay. To con-
duct the assay, test compounds were added, and the cells were
incubated at 37 °C for 5 min before the cells were lysed and
assayed for phospho-ERK using an Alphascreen-based detec-
tion kit according to the manufacturer’s protocol (PerkinElmer
Life Sciences).
Reverse Transcription-PCR—To assess FFA2 and FFA3 tran-
script expression in SW872, 3T3-L1, and STC-1 cell lines,
reverse transcription-PCRwas carried out. Total RNAwas first
isolated from cells using an RNeasy isolation kit (Qiagen). Total
RNA was treated with DNase I to eliminate any DNA contam-
ination and then used in reverse transcription reactions with
random decamer primers in order to generate cDNA. The
cDNA was used in standard PCRs with primers for mFFA2
(forward, CGAGAACTTCACCCAAGAGC; reverse, TGAGG-
GAACTGAACACCACA); mFFA3 (forward, CCCAGTGGC-
TGTGGACTTAC; reverse, CAGAAAACGTTCGATGC-
TCA); hFFA2 (forward, TCTGCTACTGGCGTTTTGTG;
reverse, AGGTGGGACACGTTGTAAGG); or hFFA3 (for-
ward, GCAGCGTGGTCTACGTCATA; reverse, CGACATG-
GGACACGTTGTAG). Because FFA2 and FFA3 are both
intronless, negative controls were carried out, where the
reverse transcriptase enzyme was omitted (RT), and positive
controls were included using either hFFA2 or hFFA3 plasmid
DNA or commercially obtained mouse genomic DNA.
SW872 and 3T3-L1 Lipolysis Assays—Differentiated SW872
or 3T3-L1 adipocytes werewashed three timeswithHBSS prior
to the co-addition of forskolin (10 M; SW872) or isoprenaline
(10 nM; 3T3-L1) to promote lipolysis, along with the test com-
pound to be assessed. Cells were incubated at 37 °C for 2 h
(SW872) or 1 h (3T3-L1), and then cell supernatants were
transferred tomicrocentrifuge tubes. Glycerol concentration in
supernatants was measured by dispensing 50 l/well in tripli-
cate into 96-well plates, followed by the addition of 50 l/well
free glycerol reagent (Sigma). Plates were then incubated at
room temperature protected from light for 15 min before
absorbance at 540 nm was measured using a Pherastar FS
microplate reader (BMG Labtech).
GLP-1 Secretion—STC-1 cells were washed with HBSS sup-
plemented with 20 mMHEPES before the addition of test com-
pound in HBSS/HEPES containing the DPPIV inhibitor
KR-62436(2.5M)topreventpeptidaseactivityandthehydroly-
sis of GLP-1. Cells were incubated at 37 °C for 1 h before cell
supernatantswere collected inmicrocentrifuge tubes. Superna-
tants were then centrifuged to eliminate any cellular debris and
assayed for GLP-1 concentration using an active GLP-1 ELISA
kit (Millipore).
Molecular Modeling—The homology model of hFFA2 was
taken from our previous study (10). Docking of compounds 1
and 2 into the model was performed using Glide 5.7
(Schrödinger, LLC, New York) of the Schrödinger computer
package. The Glide docking box was defined in the cavity
between transmembrane helices 3, 5, and 6, involving residues
at positions 5.39, 7.35, and 6.55 (in the Ballesteros and Wein-
stein numbering system (19)), because we have shown that
these residues are critical to anchor the carboxyl group of fatty
acids (18). The Glide default settings with the extra-precision
scoring option were used for docking. Images were prepared
using the Maestro 9.2 interface.
Data Analysis and Curve Fitting—All data presented repre-
sent means  S.E. of at least three independent experiments.
Data analysis and curve fitting were carried out using the
GraphPad Prism software package version 5.0b. Concentra-
tion-response data were plotted on a log axis, where the
untreated vehicle control condition was plotted at one log unit
lower than the lowest test concentration of ligand and then
fitted to three-parameter sigmoidal concentration-response
curves. Statistical analysis of curve fit parameters was carried
out by independently fitting the data from triplicate experi-
ments and comparing the resulting curve fit values by t test or
one-way analysis of variance as appropriate. Antagonism
experiments carried out with multiple fixed concentrations of
antagonist were fit where appropriate to a global Gaddum/
Schild EC50 shift equation in order to estimate pA2 values for
the antagonist.
RESULTS
Compounds 1 and 2 Are Potent and Selective FFA2 Agonists—
We synthesized two compounds based on a 4-oxobutanoic acid
backbone (compounds 1 and 2; Fig. 1A) that are related to struc-
turesdescribed in thepatent literatureasagonistsofFFA2(16) and
examined their potency and selectivity to activate FFA2 across
various functional assays. First, a [35S]GTPS incorporation assay
was employed to assess Gi/o-mediated signaling (Fig. 1B). In this
assay, compounds 1 and 2 both effectively stimulated incorpora-
tion of [35S]GTPS into membranes of Flp-InTM T-RExTM 293
cells induced to express hFFA2-eYFPwith pEC50 values of 7.14
0.08 and 6.98 0.12, respectively. These compounds were signif-
icantly (p 0.001) more potent than the endogenous ligand, C3
(pEC504.270.10), buthadefficacy similar to thatofC3 (114
4 and 94  4% of the C3 response, respectively). Because the
closely related receptor FFA3 is also a Gi-coupled GPCR, the
potential of 1 and 2 to stimulate [35S]GTPS incorporation into
equivalentmembranes fromFlp-InTMT-RExTM293cells induced
to express hFFA3-eYFPwas used to determine their selectivity for
hFFA2 over hFFA3 (Fig. 1C). In these experiments, although C3
promoted binding of [35S]GTPS with the anticipated potency
(pEC50  3.62  0.07), neither compound 1 nor 2 produced a
measurable response at up to 10 M, indicating that both com-
pounds are highly selective for hFFA2 over hFFA3.
To examine the ability of1 and2 to stimulateGq/11-mediated
pathways via activation of hFFA2, changes in intracellular Ca2
were measured in intact Flp-InTM T-RExTM 293 cells induced
to express hFFA2-eYFP (Fig. 1D). As with the [35S]GTPS
assay, both 1 and 2 did so and with significantly higher potency
(pEC50  6.68  0.06 and 6.39  0.06, respectively) than C3
(pEC50 3.50 0.10). However, in this case, both 1 and 2were
found to have significantly greater efficacy than C3 (p 0.01),
with Emax values of 132 4 and 130 4% of the C3 response,
respectively. To assess further the selectivity of 1 and 2 for
FFA2, Ca2 assays were also employed in Flp-InTM T-RExTM
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293 cells induced to express equivalent C-terminally eYFP-
tagged forms of either of the long chain free fatty acid-sensitive
GPCRs, hFFA1 and hFFA4, because both of these couple pre-
dominantly to Gq/11 G proteins. Compared with the previously
described FFA1-selective ligand TUG-424 (20), which elevated
Ca2 with pEC50  7.19  0.06 in hFFA1-eYFP-expressing
cells (Fig. 1E), 2 produced no measurable response at concen-
trations up to 10 M, whereas 1 did generate a Ca2 response
but only at the highest concentrations tested (3–10 M).
Because FFA1 agonists have at times been shown to possess
PPAR activity, we also tested whether 1 displayed agonism or
antagonism of PPAR (testing performed by Cerep, Poitiers,
France). In these experiments, 1 (10 M) was found to have no
measurable activity either as an agonist or antagonist (data not
shown).When experimentswere conducted on cells induced to
express hFFA4-eYFP (Fig. 1F), the previously described FFA4-
selective agonist TUG-891 (17) effectively increased intracellu-
larCa2 (pEC50 6.68 0.08), whereas neither1nor2had any
effect at concentrations up to 10M, indicating that 1 and 2 are
extremely selective for FFA2 over both FFA1 and FFA4.
FFA2 activationhas also been linked to increased phosphory-
lation of ERK (13), a pathway thatmay be initiated via activation
of Gi or Gq/11, as well as by G protein-independent signaling
pathways. Therefore, we explored ERK phosphorylation stim-
ulated by C3, 1, and 2 in cells induced to express hFFA2-eYFP
(Fig. 1G). In these experiments, C3 stimulated increased ERK
phosphorylation (pEC50 3.56 0.11), as did both 1 (pEC50
6.94  0.16) and 2 (pEC50  6.48  0.14). Both 1 and 2 were
significantly more potent than C3 (p  0.001), but, as in the
[35S]GTPS assay, neither 1 or 2 displayed efficacy significantly
different from that of C3. The final FFA2 signaling pathway
examined was the recruitment of -arrestin-2. Previous work
has shown that activation of hFFA2 does stimulate recruitment
of -arrestin-2 (21), an event that may be linked with GPCR
internalization and/or G protein-independent signaling. In
order to assess this, a BRET-based assaywas employed inwhich
hFFA2-eYFP and -arrestin-2 Renilla luciferase were co-ex-
pressed transiently inHEK293T cells (Fig. 1H). In this assay,C3
stimulated -arrestin-2 recruitment to human FFA2-eYFP
(pEC50 3.22 0.10), and so did both 1 (pEC50 5.72 0.10)
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FIGURE 1. Compounds 1 and 2 are potent and selective agonists of FFA2. Chemical structures of compounds 1 and 2 are shown in A. Concentration-
response curves forC3,1, and2 across various function assays are shown for hFFA2 (B,D,G, andH), hFFA3 (C), hFFA1 (E), andhFFA4 (F). Assays chosen represent
[35S]GTPS to assess Gi/o coupling (B and C), Ca
2mobilization to assess Gq/11 signaling (D–F), ERK phosphorylation (G), and -arrestin-2 recruitment (H). Error
bars, S.E.
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and 2 (pEC50 5.35 0.09). As in the other assays, both 1 and
2 were significantly more potent than C3 (p  0.001), and,
although not statistically significant (p  0.05), there was a
trend toward increased efficacy for both 1 and 2 comparedwith
C3 in this assay.
Compounds 1 and 2 Bind to the Orthosteric Pocket of FFA2—
The only series of synthetic small molecule agonists previously
published and with reasonable potency at FFA2 are allosteric in
nature and, as such, bind to a different site than the SCFAs. These
compounds, exemplifiedby4-CMTB,display reduced signaling in
some pathways and lack the carboxylate moiety that is critical in
the SCFAs for interaction with the orthosteric binding site (13).
Because 1 and 2 both contain a carboxylate functionality and dis-
play broadly similar signaling responses to C3 across all assays
tested, we hypothesized that these compounds are probably
orthosteric agonists of FFA2. To assess this, we first examined
whether the carboxylatewas critical to ligand function by generat-
ing both methyl and tert-butyl ester analogs of 2. Both of these
compounds lacked activity at hFFA2 in either [35S]GTPS incor-
poration (Fig. 2A) or-arrestin-2 interaction (Fig. 2B) assays, indi-
cating thecritical importanceof thecarboxylate to ligand function.
To confirm that this reduced functionwas due to reduced binding
of the ester ligands, we performed potential antagonism experi-
ments with each of the esters against an EC50 concentration of 2
(Fig. 2C). In such experiments, although the response to 2 was
antagonized by the previously reported hFFA2 antagonist/inverse
agonist CATPB (11), no blockade of the effect was observed with
either ester up to 100 M, indicating that the ester modifications
resulted in reduced binding affinity for these ligands rather than
converting agonism into antagonism. Because recognition of the
carboxylate moiety of the SCFAs requires arginine and histidine
residues located ineachof transmembranehelices IV–VIIofFFA2
(18), we next assessed the activity of compounds 1 and 2 at hFFA2
point mutants of each of these residues: H140A4.56 (Ballesteros
and Weinstein nomenclature in superscript), R180A5.39,
H242A6.55, and R255A7.35. As anticipated, when using -arres-
tin-2 interaction assays, activity ofC3was virtually abolished at
each of these modified receptors (Fig. 2D), and the activity of
both 1 (Fig. 2E) and 2 (Fig. 2F) was also greatly reduced in
efficacy and/or potency, indicating that interaction with these
FIGURE 2. Compounds 1 and 2 are orthosteric agonists of FFA2. Concentration-response curves at hFFA2 for C3, 2, a methyl ester of 2 (ME-Cmp 2), and a
tert-butyl ester of2 (TBE-Cmp2) are shown in [35S]GTPS (A) and-arrestin-2 recruitment (B) assays. The ability of thehFFA2 antagonist CATPB aswell asmethyl
and tert-butyl esters of 2 to inhibit an EC50 concentration of compound 2 in the -arrestin-2 recruitment assay is shown in C. Concentration-response curves
were generated using wild type and H140A, R180A, H242A, and R255Amutants of hFFA2 in the -arrestin-2 recruitment assay, and the results are shown for
C3 (D), 1 (E), and 2 (F). Antagonism experiments where concentration-response curves were generated to agonist in the presence of increasing fixed concen-
trations of CATPB are shown using C3 (G), 1 (H), and 2 (I) as agonists. Error bars, S.E.
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residues is important for function of these ligands. As addi-
tional support for an orthostericmode of binding of 1 and 2, we
compared the ability of CATPB to limit the function of C3, 1,
and 2. In ERK phosphorylation assays, increasing concentra-
tions of CATPB resulted in higher concentrations of each ago-
nist being required to cause half-maximal promotion of phos-
phorylation (Fig. 2, G,H, and I). Furthermore, in each case, the
effect of CATPB was fully overcome by sufficiently high con-
centrations of the agonist. Global curve fitting of the data
yielded similar pA2 values for CATPB of 7.23  0.09, 7.58 
0.15, and 7.24  0.14 for experiments conducted with C3, 1,
and 2, respectively. These data are consistent with competitive
interactions between each agonist and CATPB and, therefore,
with C3, 1, and 2 sharing an overlapping binding site.
Compounds 1 and 2 Are Not Modulated Allosterically by
4-CMTB—There were, however, differences between the
behavior of compounds 1 and 2 and C3. The compound
4-CMTB is recognized as an ago-allosteric modulator of FFA2
(12, 13). As a result, as well as direct activation of signaling,
increasing submaximal, fixed concentrations of 4-CMTB
increase the potency ofC3 (Fig. 3A), and vice versa (Fig. 3B). By
contrast, increasing fixed concentrations of 4-CMTB did not
alter the potency of 2 (Fig. 3C), nor did fixed concentrations of
2 alter the potency of 4-CMTB (Fig. 3D). This observation
could be consistent with either of two possibilities: 1) with so-
called “probe dependence” (22) of 4-CMTB allosterism, such
that it modulates the binding of C3 but not 2, or 2) with the
binding sites of 4-CMTB and 2 overlapping each other.
Although C3 and 2 appear to bind to the same site, whereas
4-CMTB andC3 do not, given the very small size ofC3 relative
to 2, it is still at least conceivable that 2 could overlap the bind-
ing sites of both C3 and 4-CMTB. To address this possibility,
we first examined whether the hFFA2 antagonist CATPB was
competitive with 4-CMTB by measuring the 4-CMTB concen-
FIGURE3.TheFFA2allosteric ligand4-CMTBdoesnotmodulate functionof compounds1and2.Concentration-response curves forC3 in the-arrestin-2
recruitment assay in thepresenceof increasing fixed concentrationsof 4-CMTBare shown inA. The reciprocal experiment showing the concentration response
to 4-CMTB with increasing fixed concentrations of C3 is shown in B. Similar experiments are shown using a [35S]GTPS assay with 2 and 4-CMTB (C and D). An
antagonismexperimentmeasuring theconcentration response to4-CMTB inapERKassay in thepresenceof increasing fixedconcentrationsofCATPB is shown
in E. In F, a competition experiment is shown using a fixed concentration (10 M) of the full agonist 1 with increasing concentrations of the partial agonist
4-CMTB in the -arrestin-2 BRET assay. Error bars, S.E.
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tration response in the presence of increasing concentrations of
CATPB (Fig. 3E). Interestingly, in these experiments, CATPB
did inhibit the 4-CMTB response; however, unlike with C3, 1,
and 2, where the inhibition resulted in reduced potencywith no
effect on efficacy, the inhibition of 4-CMTB by CATPB had the
opposite effect, reducing efficacy with no effect on potency.
Because we had previously shown that CATPB is competitive
with C3, 1, and 2 and therefore does not bind irreversibly, this
pattern of CATPB inhibition of the ERK response to 4-CMTB
indicates that these two molecules must bind to separate sites
and that CATPB is a negative allosteric modulator of 4-CMTB
efficacy, further strengthening the case that 2 and 4-CMTB
bind to distinct sites. Finally, to examine this more directly, we
took advantage of the fact that 4-CMTB is only a partial agonist
in theBRETassay. Therefore, if competitive, 4-CMTBwould be
expected to antagonize the response to the full agonist, 1, mea-
sured in this assay (Fig. 3F). In these experiments, 1 produced a
maximal response that was 156  12% of the C3 response,
whereas 4-CMTB was a partial agonist producing a maximal
response that was only 51 4% of theC3maximum. However,
when increasing concentrations of 4-CMTB were used with a
fixed, high concentration of 1, there was no inhibition, and
indeed there was a small increase in response, with increasing
concentrations of 4-CMTB. Taken together, these results sug-
gest strongly that both 1 and 2 are binding to a distinct site to
4-CMTB and that, therefore, the lack of allosterism between
these two compounds represents a probe dependence in the
ability of 4-CMTB to modulate function of FFA2 orthosteric
agonists.
ECL2 Is Critical to the Binding and Selectivity of Compounds
1 and 2—We next considered whether the probe-dependent
effect of 4-CMTBmight be instructive in defining the mode or
location of binding of 1 and 2. A recent study demonstrated
that replacement of ECL2 of hFFA2 with the equivalent region
from hFFA3 has no negative effect on the potency of C3 or
4-CMTB but essentially eliminates allosteric communication
between the binding sites of these ligands (13). We considered,
therefore, if the lack of allosteric interactions between 4-CMTB
and 2 reflects that these ligands interact with ECL2 in such a
way as to prevent allosteric communication. We tested this by
comparing the potency ofC3, 1, and 2 in a -arrestin-2 recruit-
ment assay at wild type hFFA2 and the variant in which ECL2 is
replaced by this sequence from hFFA3 (13). As observed previ-
ously, this modification resulted in a modest increase in the
potency ofC3, pEC50 of 3.84 0.013 at the ECL2 swapmutant
compared with 3.23  0.07 at wild type (Fig. 4A). By contrast,
for both 1 (Fig. 4B) and 2 (Fig. 4C), marked reductions in
potency were observed. In addition to showing broadly that
ECL2 is important for allosteric communication between C3
and 4-CMTB, Smith et al. (13) also identified a single point
mutation in ECL2 of hFFA2, L173A, which also eliminated
allosteric communication. This alteration did not affect the
potency ofC3 in the-arrestin-2 interaction assay (Fig. 4D) but
resulted, however, in a significant (p  0.01) decrease in
potency for both 1 (pEC50 of 5.29  0.11 at L173A compared
with 5.99  0.07 at wild type (Fig. 4E)) and 2 (pEC50 values of
4.93 0.11 and 5.54 0.08 at L173Aandwild type, respectively
(Fig. 4F)).
Because the hFFA2/hFFA3 ECL2 swap mutant substantially
lost potency to both 1 and 2, we next explored if ECL2 repre-
sents a key region in defining the selectivity of these compounds
for hFFA2. To do so, we employed sequence alignment to iden-
tify residues in ECL2 conserved between FFA1 and FFA3, but
not FFA2. This search yielded one obvious residue, where a
FIGURE 4.Extracellular loop2 is critical to the functionof compounds1 and2at hFFA2.Concentration responses toC3 (A),1 (B), and2 (C) are shownusing
the-arrestin-2 recruitment assay for wild type hFFA2 aswell as for a chimeric formof hFFA2where its ECL2 has been replacedwith the ECL2 of hFFA3. Similar
experiments show concentration responses to C3, 1, and 2 (D–F) at wild type hFFA2 and the L173A point mutant of hFFA2. Error bars, S.E.
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glutamic acid is present in hFFA1 (position 145) and hFFA3
(position 152) but is a glutamine in hFFA2 (position 148). Pre-
vious work has shown that alteration of Glu-145 to alanine in
FFA1 breaks an extracellular ionic lock and increases ligand-
independent constitutive activity (23). We therefore generated
both Q148E and Q148A mutants of hFFA2 to test whether a
similar ionic lock might influence the FFA2 selectivity of 1 and
2. These mutants were first assessed in the -arrestin-2 assay
with C3 (Fig. 5A), 1 (Fig. 5B), and 2 (Fig. 5C). Although the
potency of C3 was reduced some 10-fold at the Q148E mutant
(pEC50  3.27  0.10 at wild type and 2.34  0.11 at Q148E),
both 1 and 2 were virtually inactive at this mutant. In contrast,
C3 did not show reduced potency at the Q148A mutant
(pEC50 3.35 0.08), and although both had reduced efficacy,
neither 1 nor 2 displayed significant loss in potency at the
Q148Amutant. Because the potency of agonists in the -arres-
tin-2 assay generally reflects receptor occupancy and hence is a
surrogate measure of affinity, this suggests that the presence of
a glutamate but not alanine at this position significantly reduces
the binding of both 1 and 2 to hFFA2. To explore this further,
we also employed the ERK assay because this often provides
higher agonist potency values due to the effects of receptor
reserve (24). Here, the potency ofC3 (Fig. 5D) was little affected
atQ148E comparedwithwild type hFFA2 (pEC50 3.89 0.11
forwild type and 3.76 0.07 atQ148E), whereas for both 1 (Fig.
5E) and 2 (Fig. 5F), there was again a nearly complete loss of
agonist function. These results confirm that the lack of gluta-
mate at this position in FFA2 is critical to the binding of 1
and 2 and therefore potentially could be involved in the
selectivity of these compounds. To test whether this position
contributes to the selectivity, we generated the reciprocal
E145Q and E154Q mutants of hFFA1 and hFFA3, respec-
tively. Interestingly, although the E145Q mutant did not
alter the potency of the FFA1 agonist TUG-424 in a -arres-
tin-2 recruitment assay (Fig. 5G), it did result in a clear gain
of function for 1 when compared against wild type hFFA1
FIGURE 5. The absence of a glutamate residue in ECL2 of FFA2 that is present in both FFA1 and FFA3 defines the FFA2 selectivity of compound 1 and
2. Concentration responses are shown using the -arrestin-2 recruitment assay for C3 (A), 1 (B), and 2 (C) at wild type, Q148E, and Q148A variants of hFFA2.
Similar pERK experiments are shownwithwild type andQ148E hFFA2 (D–F).-Arrestin-2 recruitment towild type and the E145Qmutant of hFFA1 is shown for
TUG-424 (G), 1 (H), and 2 (I). Error bars, S.E.
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(Fig. 5H) but did not significantly alter the response for 2
(Fig. 5I). Similar experiments were conducted on the equiv-
alent E154Q mutant of hFFA3 in [35S]GTPS experiments;
however, this mutant was found to completely lack function
to all ligands tested (data not shown).
Molecular Modeling Suggests Further Interactions within the
Transmembrane Domains of hFFA2 for Compounds 1 and 2—
Predictions and modeling of extracellular loop regions of GPCRs
remain highly speculative and challenging, particularly for recep-
tors well removed phylogenetically from those for which atomic
level structures are available. By contrast, the overall architecture
of the transmembrane helix bundle is generally well preserved
among GPCRs. As such, confidence in homologymodels of these
regions is increasing, and well validated models are becoming
widely used in suggesting likely ligand-receptor interactions
within these regions. FFA2 homology models have provided
important insights into modes of orthosteric ligand binding and
differences in this between species orthologs (13, 18, 21). We
therefore employed homology modeling of hFFA2 and ligand
docking methods to suggest additional residues that might con-
tribute to the enhancedpotencyof1 and2 comparedwithC3 (Fig.
6, A and B). Based on such models, five transmembrane residues
and one additional ECL2 residue were highlighted for subsequent
analysis. Each of these was mutated to alanine and assessed with
C3, 1, and 2 in a [35S]GTPS incorporation assay (Table 1). From
these studies, it was apparent that several mutants (i.e. Y90A3.29,
Y165AECL2, and Y238A6.51) displayed significantly lower potency
to each ligand, indicating their likely contribution to the
orthosteric binding pocket by forming hydrophobic and aromatic
interactions. Inaddition,Tyr-165might alsocontribute in steering
the ligand into the binding cavity. The I145A4.61mutant appeared
to not be expressed andproducedno response to any ligand.Most
interestingly in the current context, although the V179A5.38
mutant did not alter potency for C3 (Fig. 6C), it did result in a
significant reduction in potency for both 1 (p 0.01; Fig. 6D) and
2 (p0.05; Fig. 6E).Ourdocking results predict that the cyclopro-
pyl ring of 1 and 2 forms hydrophobic contacts with V179A5.38.
Overall, the ligands 1 and 2 have more contacts with the residues
of helices 3, 5, and 6 in the extracellular part of the helical bundle
that remarkably impact the potency of the ligands when the resi-
dues are mutated to alanine.
Compounds 1 and 2 Display Differential Function at Rodent
Orthologs of FFA2—Recent work has demonstrated that FFA2
displays significant species ortholog variation with respect to
both the endogenous SCFA ligands and to the synthetic antag-
onist CATPB (11, 21). Considering this, it was important to
FIGURE 6.Molecularmodeling andmutagenesis reveals key transmembrane residues involved in the binding of compounds 1 and2 (Cmp1 andCmp
2). A and B, the predicted binding pose of compounds 1 and 2 in the hFFA2 homology model and two-dimensional schematic representations of these are
displayed. Residues forming contacts with the ligands are shown as gray sticks, and the receptor C atoms are colored based on the residue position within
individual transmembrane domains. In the scheme to the right of each homology model, the residues are colored based on their physicochemical properties
and scaledbased on the distance to the two-dimensional plane. Hydrogen bonds and- aromatic stacking are indicated by dotted pink and continuous green
lines, respectively. Error bars, S.E.
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establish whether similar species ortholog variation might
affect the usefulness of 1 and 2 in non-human systems. For this,
we compared the activity of C3, 1, and 2 at each of the human,
mouse, and rat orthologs of FFA2 across multiple assay end
points (Table 2). Initially, we examined the responses of C3
(Fig. 7A), 1 (Fig. 7B), and 2 (Fig. 7C) at each ortholog in the
Gi/o-dependent [35S]GTPS assay. Consistent with previous
reports (11), C3 displayed significantly (p  0.01) lower
potency at mFFA2 and rFFA2 compared with hFFA2. Interest-
ingly, although 1 also displayed a reduction in potency (p 
0.05) of approximately the same magnitude as C3 at mFFA2
(3.9-fold) and rFFA2 (5.4-fold) compared with hFFA2, 2 dis-
played a much larger reduction in potency at both mFFA2 (20-
fold) and rFFA2 (22-fold) compared with hFFA2. Similar
results were obtained when these compounds were assessed at
the species orthologs in a Ca2 assay tomeasure Gq/11-coupled
signaling (Fig. 7, D–F), with a much greater reduction in
potency observed for 2 than for C3 or 1. In addition, because 1
was found to have some activity at hFFA1, we also tested these
compounds at mFFA1 in a Ca2 assay, finding no activity for 2
and only weak activity for 1, requiring at least 10M before any
Ca2 response was observed (data not shown).
In ERK phosphorylation assays, similar potencies were
observed for C3 at hFFA2, mFFA2, and rFFA2 (Fig. 7G), and a
small reduction in potency at the rodent orthologs was
observed with 1 (Fig. 7H), whereas, once more, a substantial
reduction in potency was seen for 2 (Fig. 7I). We have recently
demonstrated that utilizing the variation in pharmacology
between species orthologs of FFA2 can be a valuable approach
in defining key aspects of receptor function (11, 21). Therefore,
we next examined whether we could take advantage of the spe-
cies differences in the function of C3, 1, and 2 to help further
define important and differential aspects of their function. First
we considered a possible explanation for the broad decrease in
potency we observed across all ligands. Recently, we have dem-
onstrated that the absence in hFFA2, or presence in mFFA2, of
an ionic lock between a glutamate residue at position 159 in
ECL2 and arginine residues within the orthosteric binding
pocket accounts for both reduced constitutive activity and
lower SCFA potency at the mouse ortholog (11). Therefore, we
hypothesized that this same residue might account for the
broad decrease in potency we observed across all ligands. To
assess this, we compared the ability of C3 (Fig. 8A), 1 (Fig.
8B), and 2 (Fig. 8C) to produce a Ca2 response via either
wild type hFFA2 or a G159E hFFA2 mutant. In these exper-
iments, despite similar levels of expression, C3 displayed
significantly reduced potency at the G159E mutant com-
pared with wild type (pEC50  4.26  0.06 at wild type and
3.69  0.06 at G159E). Similarly, 1 displayed reduced
potency (7.06 0.11 at wild type compared with 6.32 0.07
at G159E), as did 2 (6.66  0.06 at wild type and 6.28  0.07
at G159E). Interestingly, the magnitude of potency decreases
observed at the G159E mutant were similar for C3 (3.7-fold)
and 1 (5.5-fold) to the potency decreases observed for these
compounds at the two rodent orthologs compared with
human FFA2 in the Ca2 assay (	4.5-fold for C3 and 	12-
fold for 1). In contrast, the potency decrease for 2 was only
2.4-fold at the G159E hFFA2 mutant, substantially less than
the decrease observed for rodent compared with human
orthologs in the Ca2 assay using this ligand (416-fold for
mFFA2 and 154-fold for rFFA2). These results indicate that
the presence or absence of this “ionic lock” accounts for the
broad decrease in potency seen for all agonist ligands at the
rodent orthologs but does not account for the substantially
greater loss in potency observed with 2.
Toattempt tounderstand this selective reduction inpotency for
2,we re-examined thehomologymodelswith1or2docked (Fig. 6,
A and B) with the aim of identifying key residues predicted to be
involved in ligand interaction in thehumanortholog thatwerenot
conserved in the mouse and rat orthologs. This yielded only one
residue in proximity to the defined orthosteric pocket, serine
863.29 in hFFA2, which is glycine in both rFFA2 and mFFA2. We
hencegeneratedanS86GmutantofhFFA2andexamined its func-
tion across several assays. Initially, we tested this mutant in the
-arrestin-2recruitmentassay,where, althoughthisalterationhad
no significant effect on the potency of eitherC3 (Fig. 9A) or 1 (Fig.
TABLE 1
Potency of C3, 1, and 2 in a [35S]GTPS assay to activate FFA2 and FFA2mutants
Mutant Expressiona C3b Compound 1b Compound 2b
hFFA2 100 4.12 0.12 (100) 7.10 0.12 (101 6) 6.94 0.09 (107 5)
Y90A 81 9 2.35 0.26 (43 11) 5.5 5.5
I145A 2.6 2 NRc NR NR
Y165A 33 3 2.87 0.47 (30 12) 6.45 0.42 (40 13) 5.5
V179A 100 6 4.28 0.16 (48 3) 6.06 0.25 (55 11) 5.67 0.57 (42 24)
L183A 14 1 4.04 0.14 (72 4) 7.16 0.20 (83 8) 6.79 0.18 (81 8)
Y238A 40 2 2.76 0.26 (38 8) 5.5 5.5
a eYFP signal measured in membranes expressing each mutant expressed as the percentage of the eYFP fluorescence signal measured from the hFFA2WTmembranes.
b pEC50 values are reported with efficacy expressed as a percentage of the C3 response at wild type hFFA2 in parenthesis.
c NR, no response.
TABLE 2
Potency of C3, 1, and 2 at human and rodent orthologs of FFA2 across
various functional assays
hFFA2 mFFA2 mSelect.a rFFA2 rSelect.b
[35S]GTPS
C3 4.10 0.12 3.57 0.10 0.53 3.57 0.13 0.53
1 6.86 0.07 6.27 0.13 0.59 6.13 0.14 0.73
2 6.79 0.10 5.48 0.16 1.31 5.43 0.26 1.36
Ca2
C3 3.89 0.07 3.21 0.09 0.68 3.24 0.07 0.65
1 6.71 0.07 5.57 0.10 1.14 5.61 0.07 1.10
2 6.39 0.06 3.77 0.17 2.62 4.20 0.09 2.19
pERK
C3 3.50 0.10 3.52 0.09 0.02 3.74 0.10 0.24
1 6.80 0.11 6.23 0.12 0.57 6.41 0.09 0.39
2 6.26 0.12 4.5 1.76 4.5 1.76
a mSelect., the preference for ligand at hFFA2 over mFFA2. Values represent the
difference in pEC50 obtained between species orthologs in the same assay.
b rSelect., the preference for ligand at hFFA2 over rFFA2. Values represent the
difference in pEC50 obtained between species orthologs in the same assay.
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9B), it did result in a significant reduction of potency of2 (Fig. 9C).
Similar results were observed when the S86G hFFA2mutant was
tested in both Ca2 (Fig. 9, D–F) and ERK (Fig. 9, G–I) assays.
Although the decreases in potency for 2 at S86G compared with
wild type hFFA2 (7-fold in the -arrestin-2 assay, 10-fold in the
Ca2 assay, and 8-fold in the pERK assay) were not as large as the
decrease observed for 2 at the rodent ortholog compared with
human FFA2, this site clearly contributes to the specific reduction
in potency for 2 in the rodent orthologs. Indeed, it is likely that a
combination of the effects of the presence of Gly-86 and Glu-159
residues in rat and mouse FFA2 accounts for the bulk of potency
loss observed for 2 at the rodent orthologs.
Compounds 1 and 2 Demonstrate FFA2-mediated Inhibition
of Lipolysis in Human Adipocytes, whereas Only Compound 1
Effectively Inhibits Lipolysis in Mouse Adipocytes—Having
defined the potency and activity of C3, 1, and 2 in cells trans-
FIGURE7.Compound2andtoasubstantially lesserextentcompound1showsreducedpotencyat rodentorthologsofFFA2.Concentration responses forC3
(A,D, andG),1 (B, E, andH), and2 (C, F, and I) are shownat human,mouse, and rat orthologs of FFA2 in [35S]GTPS (A–C), Ca2 (D–F), andpERK (G–I) assays. Error bars,
S.E.
FIGURE8.Theabsenceofan ionic lock inhFFA2accounts for thegreaterpotencyofC3, 1, and to someextent2at thehFFA2comparedwith the rodent
orthologs.Concentration responses forC3 (A),1 (B), and2 (C) are shown in aCa2mobilization assayusingwild type andG159EhFFA2. The relative expression
of wild type and G159E was assessed by measuring eYFP fluorescence and is shown as an inset to A. Error bars, S.E.
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fected to express each of the human,mouse and rat orthologs of
FFA2 in a heterologous manner, this provided the opportunity
to define the specific role of FFA2 in functional responses of
cells endogenously expressing the receptor. To do so, we exam-
ined the effects of these ligands on stimulated lipolysis in both a
human-derived liposarcoma cell line, SW872, and in mouse
3T3-L1 cells, after differentiating each cell line into adipocyte-
like phenotypes. Initial RT-PCR studies on mRNA isolated
from differentiated SW872 and 3T3-L1 cells confirmed expres-
sion of FFA2 but not FFA3 in each cell type (Fig. 10, A and B).
To examine lipolysis in the differentiated SW872 line, cells
were treated with 10 M forskolin to stimulate lipolysis, which
was then measured by assessing the concentration of glycerol
released into the cell culture supernatant (Fig. 10, C–E). Unex-
pectedly, treatment with C3 (10 mM) enhanced lipolysis in
these cells markedly. However, this effect was not blocked by
the hFFA2 antagonist CATPB. In contrast, both 1 (10 M) and
2 (10 M) significantly reduced (p  0.05) glycerol release to
79 9 and 79 15%of the forskolin alone control, respectively.
Importantly, for both 1 and 2, the effect of the ligand was com-
pletely reversed by the hFFA2 antagonist CATPB.
Toassess lipolysis in the3T3-L1adipocytes,we first treatedcells
with high concentrations of C3 (10 mM), 1 (10 M), or 2 (10 M)
and measured inhibition of isoprenaline-stimulated glycerol
release (Fig. 10F). BothC3 (p 0.01) and1 (p 0.05) significantly
inhibited glycerol release, whereas 2 did not. Although failing to
reach statistical significance,C3 tended to produce a greater inhi-
bitionof glycerol release, 5410%, comparedwithonly380.5%
for 1. Finally, in concentration-response experiments, C3 inhib-
itedglycerol releasewith apIC503.240.36 (Fig. 10G),whereas
1was some480-foldmorepotent (pIC505.920.43) (Fig. 10H),
and 2 was again without significant effect (Fig. 10I). Because the
only FFA2 antagonist currently available, CATPB, is highly
human-selective, it was not possible to perform studies to block
these effects with an FFA2 antagonist. However, because we had
demonstrated that 1 has low potency agonism at FFA1, we did
confirm that the effect of compound 1 was not blocked by the
FFA1 antagonist GW1100 (data not shown). These results dem-
onstrate that FFA2 inhibits lipolysis in both human- and rodent-
derived adipocytemodels and that, despite their chemical similar-
ity, compound 1 but not compound 2 is a novel and valuable tool
to specifically assess the function of FFA2 in murine cells and
tissues.
Compound 1 Stimulates GLP-1 Release from Murine STC-1
Enteroendocrine Cells—Having shown that 1 can be used to
assess FFA2 function in mouse cells endogenously expressing
FIGURE 9. The reduced function of compound2 at rodent FFA2orthologs results from thepresence of glycine at position 86, comparedwith serine at
this position in hFFA2. Concentration-response curves are shown at wild type and S86G hFFA2 in-arrestin-2 (A–C), Ca2mobilization (D–F), and pERK (G–I)
assays using C3, 1, or 2. Error bars, S.E.
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the receptor, we finally set out to use this compound to selec-
tively examine FFA2 versus FFA3 function in cells endoge-
nously co-expressing both receptors. For this, we examined the
release of GLP-1 from the mouse-derived enteroendocrine cell
line STC-1, which we confirmed by RT-PCR to express both
FFA2 and FFA3 (Fig. 11A). Treatment of these cells with C3 (1
or 10 mM) or 1 (10 M) significantly increased GLP-1 secretion
(p 0.001). Interestingly, there was no difference in the maxi-
mum GLP-1 response produced by C3 or 1, indicating that C3
is probably stimulating GLP-1 release primarily through FFA2
and not FFA3 in this cell line.
DISCUSSION
In cases where closely related GPCRs respond to the same
endogenous ligand(s), developing selective synthetic agonists
or antagonists capable of differentiating between the receptors
is critical to defining their individual biological roles. This is the
case for FFA2 and FFA3 because each responds to the same
endogenous SCFA ligands. Differences in the rank order of
potency have been described for the SCFAs at FFA2 compared
with FFA3 (4). However, the potency and selectivity of these
compounds remains low. As a result, very high concentrations
of SCFAs must be used, and, because the SCFAs are known to
have additional off-target effects, including, for example, inhi-
bition of histone deacetylases (25), this hasmade attributing the
biological effects of SCFAs directly to FFA2 or FFA3 challeng-
ing. Further complicating the issue is the recent observation
that C2, a SCFA with a degree of selectivity for hFFA2 over
hFFA3, does not show this selectivity at the rodent orthologs of
these receptors (11), making it effectively impossible to clearly
define FFA2 versus FFA3 functions using SCFAs in rodent
models without knock-out approaches. Although such knock-
out studies have been informative in this respect (8, 9, 14, 26,
27), there is also evidence that knock-out of FFA3 results in
reduced FFA2 expression (8), clearly complicating the interpre-
tation of data based upon such animals.Moreover, in studies on
the possible contribution of FFA2 to gut inflammatory disease,
two distinct lines of FFA2 knock-out mice generated entirely
contradictory results, in that in a model of colitis, one line dis-
FIGURE 10. Compounds 1 and 2 define the role of FFA2 in the inhibition of lipolysis in human- andmurine-derived adipocyte cell lines. Expression of
FFA2 and FFA3 transcripts in differentiated SW872 and 3T3-L1 adipocytes was assessed by RT-PCR and is shown in A and B, respectively. No-template control
reactions (NTC), reactions without reverse transcriptase (RT), reactions with reverse transcriptase (RT), and plasmid (pDNA)/genomic DNA (gDNA)-positive
control reactions are shown. The effect ofC3 (10mM),1 (10M), and2 (10M) on forskolin (Forsk) (10M)-stimulated lipolysis in SW872 is shown inC–E. In each
case, the ability of the hFFA2 antagonist, CATPB (10 M), to block ligand response is also shown. The effect of single, high concentrations of C3 (10 mM), 1 (10
M), and2 (10M) to inhibit isoprenaline (ISO) (10 nM)-induced lipolysis in differentiated 3T3-L1 adipocytes is shown in F. **,p 0.01; *,p 0.05. Concentration
responses are shown for C3 (G), 1 (H), and 2 (I) in the 3T3-L1 inhibition of lipolysis assay. Error bars, S.E.
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played reduced and the other exaggerated inflammation (26,
27). To address such issues, there is a clear need for synthetic
ligands that can effectively differentiate between FFA2 and
FFA3 in both human and non-human experimental systems.
Although several synthetic ligands have been reported with
selectivity for either FFA2 or FFA3 (10–13, 28), each of these
suffers from either poor potency, low selectivity, altered func-
tion due to an allosteric mode of action, or lack of function at
non-human orthologs of the receptors. Therefore, our descrip-
tion of compounds 1 and 2 as the first potent and selective
orthosteric agonists of hFFA2 and of 1 as the first orthosteric
compound displaying reasonable activity at rodent orthologs of
FFA2 suggests that these compounds will be extremely useful
tools in future studies designed to define the specific biological
role of this receptor.
To demonstrate the usefulness of compounds 1 and 2 in this
respect, we demonstrated that both compounds inhibit lipoly-
sis in human-derived SW872 cells, whereas only compound 1
does in murine 3T3-L1 adipocytes. Previous studies have indi-
cated that SCFAs inhibit lipolysis in adipocytes and that this
occurs via a Gi/o-dependent mechanism (9, 12). However, at
least in SW872 cells, this was not the case because C3 actually
markedly enhanced lipolysis, although via a mechanism that
did not involve FFA2 because this effect was not blocked by the
hFFA2 antagonist CATPB. This observation indicates that C3
has additional cellular targets in SW872 cells and that any effect
on lipolysis it may have through FFA2 is effectively masked by
these much larger “off-target” effects. Clearly, this highlights a
major challenge to using only SCFA ligands to assess FFA2
function that can only be addressed through the development
of more potent and selective ligands, such as compound 1.
In the 3T3-L1 cells, it is interesting to note that the potency of
both C3 and 1 to inhibit lipolysis (3.24 0.36 and 5.92 0.43,
respectively) was very similar to the values we measured at
mFFA2 for these compounds in the [35S]GTPS assay (3.57 
0.10 and 6.27  0.13, respectively), a measure of Gi/o-depen-
dent signaling.We also noted that, although not quite reaching
statistical significance, there was a trend toward C3 producing
a greater maximum inhibition of lipolysis than 1. This could
reflect either that 1 acts as a partial agonist relative toC3 in this
signaling response or that C3 also has additional non-FFA2
targets in murine adipocytes that also modulate lipolysis. How-
ever, given that we observe little sign of partial agonism for 1 in
other assays employingmFFA2, off-target effects ofC3 perhaps
represent the more likely explanation. Although we were
unable to detect mFFA3 mRNA in the differentiated 3T3-L1
model adipocytes, certain studies have reported FFA3 expres-
sion in adipocytes (5), whereas another noted altered adipocyte
function in FFA3 knock-out mice (8). Indeed, although the
expression of FFA3 in adipocytes remains controversial (4), it is
at least conceivable that, despite a lack of detection of mRNA,
low levels ofmFFA3 proteinmay be expressed in these cells and
could account for the greater efficacy of C3 relative to 1.
Another critical feature of compound 1 in addition to retain-
ing activity at the rodent orthologs of FFA2 is that it is
extremely selective for FFA2 over FFA3. This should allow for
the delineation of FFA2-mediated responses in cells that co-ex-
press both receptors as we were able to do in demonstrating
that FFA2, rather than FFA3, mediates GLP-1 release from
STC-1 cells. The similar efficacy of C3 and 1 in this assay sug-
gests that despite expressing FFA3, GLP-1 secretion by these
cells in response to C3 is predominantly through FFA2, a con-
clusion consistent with previous work (29).
It is somewhat surprising that such substantial differences in
activity were observed between 1 and 2 at the rodent orthologs
of FFA2, given their structural similarity. Indeed, the primary
structural difference between the two compounds (in addition
to different positions for their chlorine substituents) is the pres-
ence of a phenyl substituent in 1, which is cyclopentyl in 2.
Interestingly, closer examination of the docking of these com-
pounds to our homology model of hFFA2 shows that this phe-
nyl/cyclopentyl substituent is predicted to be in close proximity
to Ser-86, the position we have found that when mutated to
glycine (the amino acid present in rodent forms of FFA2) results
in substantial loss of potency only for the cyclopentyl contain-
ing 2. This appears to be consistent with this position being
critical to the reduced potency of 2 at the rodent orthologs and
perhaps suggests that replacing the serine residue with a
smaller glycine residue affects the position and orientation of 2
in the binding cavity, resulting in less favorable contacts with
other residues. It also must be noted that, given the marked
variation in function of 1 and 2 at the rodent orthologs, future
studies that further extend the structure-activity relationship of
these compounds, particularly by modification of the phenyl/
cyclopentyl substituent, may provide a good approach to iden-
tify compounds with even better activity at the rodent
orthologs. Finally, an obvious corollary of these findings is that
because only small chemical differences between 1 and 2 result
in profoundly different functional consequences between spe-
cies orthologs of FFA2, any future ligands in this series will also
need to be assessed empirically across species before being con-
sidered as useful tool compounds.
FIGURE 11. Compound 1 stimulates GLP-1 release in the murine STC-1
enteroendocrine cell line. Expression of FFA2 and FFA3 transcripts in STC-1
cells is shown in A. No-template control reactions (NTC), reactions without
reverse transcriptase (RT), and reactions with reverse transcriptase (RT)
are shown. The ability of varying log(M) concentrations C3 (gray bars) or 1
(blackbars) to stimulateGLP-1 secretion fromthese cells is shown inB. ***,p
0.001 compared with DMSO vehicle treatment. Error bars, S.E.
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Our observation that ECL2 contributes to both the binding
and selectivity of compounds 1 and 2 is also of note. Interest-
ingly, the structure of the extracellular loops, and in particular
ECL2, varies greatly among the GPCRs for which crystal struc-
tures are available (30, 31). However, despite (or perhaps
because of) this, there are several examples of GPCRs where
ligand selectivity is defined at least in part by ECL2 (30, 31). It is,
therefore, perhaps not surprising that mutation of a single res-
idue in ECL2 of FFA2, Gln-148, to glutamate, as it is in FFA1
and FFA3, could result in loss of potency to these ligands,
whereas the reciprocal mutation, at least in FFA1, would result
in a gain in function. The specific mechanism underlying how
this residue may dictate FFA2 versus FFA1 selectivity may also
be of interest. Previous work has shown that an ionic lock
between this position in FFA1 andone of twopositively charged
arginine residues within the fatty acid binding pocket of this
receptor regulates constitutive activity of FFA1 (23). We have
also recently shown that similar ionic locks involving additional
positions within ECL2 regulate constitutive activity in human
and rodent orthologs of FFA2 and FFA3 (11). Therefore, it is
tempting to hypothesize thatmutation of Gln-148 to glutamate
in hFFA2 allows for the formation of an ionic lock at this posi-
tion similar to that present in FFA1 and that this effectively
closes off the binding pocket to 1 and 2. By contrast, in FFA1,
mutation of Glu-145 to glutamine would alleviate this ionic
lock, thus allowing for increased binding by these ligands. To
more directly test this, we also generated the Q148Amutant of
hFFA2 and found that, unlike the Q148E mutant, the alanine
mutant did not show reduced potency to 1 and 2. This obser-
vation indicates that it is the gain of the negatively charged
glutamate, and not the loss of glutamine that results in reduced
potency to 1 and 2, a finding that appears to support the ionic
lock hypothesis.
It was interesting that 1 did possess some activity at wild type
FFA1, as well as increased activity at the E145Qmutant. This is
perhaps surprising, given that there is no overlap in the endog-
enous ligands activating these receptors, nor have any previ-
ously described synthetic ligands for FFA1 been found to have
activity at FFA2 (20, 32–37). The fact that 1 does show some
activity at FFA1 indicates that there is at least some similarity in
the tertiary structure of the binding pockets of these receptors
and perhaps indicates that counterscreening FFA1 agonists
against FFA2 and FFA3 as well as for FFA4 and PPAR activity
should be more routinely carried out in the future. The obser-
vation that1wasmore active at bothwild type andE145QFFA1
than was 2 is also strikingly similar to the pattern of activity
these compounds have at rodent FFA2. Because we have dem-
onstrated that a glycine instead of serine at position 863.29
accounts for this effect in rodent FFA2, we note that FFA1 pos-
sesses alanine at this 3.29 position, a residue that is also non-
polar and smaller compared with the serine present in hFFA2.
This may suggest that the preference for 1 over 2 in FFA1 is
perhaps dictated by factors similar to those that dictate this
same preference in rodent FFA2.
We have described the first potent and selective orthosteric
agonists of FFA2 anddefined themolecular basis for their inter-
actionwith the receptor. Our demonstration that at least one of
these ligands can be used to delineate specific FFA2 function in
murine cell systems highlights the importance these com-
pounds may have, particularly in possible future, preclinical
drug development and proof-of-principle studies at this recep-
tor. FFA2 represents an interesting therapeutic target for the
treatment of various metabolic and inflammatory conditions
(28), forwhich development has been slowedprimarily by a lack
of reasonably potent and selective ligands (4). Therefore, the
description of compound 1 as tool to study FFA2 function as
well as our detailed examination of the molecular basis for its
potency and selectivity, which should aid in future ligand devel-
opment at these receptors, will be invaluable to exploring the
potential of FFA2 as a therapeutic target.
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